|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCL16 |
Gene summary for CCL16 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCL16 | Gene ID | 6360 |
| Gene name | C-C motif chemokine ligand 16 | |
| Gene Alias | CKb12 | |
| Cytomap | 17q12 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | O15467 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6360 | CCL16 | HCC1_Meng | Human | Liver | HCC | 1.67e-33 | 1.10e-01 | 0.0246 |
| 6360 | CCL16 | HCC1 | Human | Liver | HCC | 8.07e-24 | 4.44e+00 | 0.5336 |
| 6360 | CCL16 | HCC2 | Human | Liver | HCC | 3.85e-10 | 2.00e+00 | 0.5341 |
| 6360 | CCL16 | Pt14.a | Human | Liver | HCC | 5.94e-08 | 4.72e-01 | 0.0169 |
| 6360 | CCL16 | Pt14.b | Human | Liver | HCC | 2.20e-07 | 3.52e-01 | 0.018 |
| 6360 | CCL16 | Pt14.d | Human | Liver | HCC | 2.25e-02 | 1.78e-01 | 0.0143 |
| 6360 | CCL16 | S014 | Human | Liver | HCC | 1.52e-21 | 9.47e-01 | 0.2254 |
| 6360 | CCL16 | S015 | Human | Liver | HCC | 4.24e-30 | 1.78e+00 | 0.2375 |
| 6360 | CCL16 | S016 | Human | Liver | HCC | 6.73e-27 | 1.12e+00 | 0.2243 |
| 6360 | CCL16 | S028 | Human | Liver | HCC | 1.00e-03 | 2.28e-01 | 0.2503 |
| 6360 | CCL16 | S029 | Human | Liver | HCC | 1.98e-10 | 6.18e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00343411 | Liver | HCC | response to interferon-gamma | 82/7958 | 141/18723 | 1.25e-04 | 1.03e-03 | 82 |
| GO:00713461 | Liver | HCC | cellular response to interferon-gamma | 70/7958 | 118/18723 | 1.66e-04 | 1.32e-03 | 70 |
| GO:00705551 | Liver | HCC | response to interleukin-1 | 80/7958 | 143/18723 | 7.95e-04 | 4.77e-03 | 80 |
| GO:003461211 | Liver | HCC | response to tumor necrosis factor | 132/7958 | 253/18723 | 1.14e-03 | 6.48e-03 | 132 |
| GO:00713471 | Liver | HCC | cellular response to interleukin-1 | 61/7958 | 113/18723 | 8.98e-03 | 3.46e-02 | 61 |
| GO:007135611 | Liver | HCC | cellular response to tumor necrosis factor | 115/7958 | 229/18723 | 1.08e-02 | 3.99e-02 | 115 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCL16 | insertion | Frame_Shift_Ins | novel | c.246_247insAGGCGTGAGCCACCACATCCGGCCAGTGCACTCTTAATACACAGAAA | p.Trp83ArgfsTer70 | p.W83Rfs*70 | O15467 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CCL16 | SNV | Missense_Mutation | novel | c.275N>G | p.Asn92Ser | p.N92S | O15467 | protein_coding | tolerated(0.32) | benign(0.026) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CCL16 | SNV | Missense_Mutation | novel | c.164N>T | p.Arg55Ile | p.R55I | O15467 | protein_coding | tolerated(0.19) | benign(0.062) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| CCL16 | SNV | Missense_Mutation | novel | c.320T>A | p.Ile107Asn | p.I107N | O15467 | protein_coding | deleterious_low_confidence(0.01) | benign(0.154) | TCGA-F4-6704-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
| CCL16 | SNV | Missense_Mutation | rs199602184 | c.56N>T | p.Ser19Leu | p.S19L | O15467 | protein_coding | tolerated(0.08) | benign(0.01) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| CCL16 | SNV | Missense_Mutation | novel | c.169N>A | p.Ala57Thr | p.A57T | O15467 | protein_coding | tolerated(0.25) | benign(0.246) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| CCL16 | SNV | Missense_Mutation | novel | c.148N>A | p.Leu50Ile | p.L50I | O15467 | protein_coding | tolerated(0.1) | possibly_damaging(0.57) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CCL16 | SNV | Missense_Mutation | novel | c.43N>A | p.Leu15Ile | p.L15I | O15467 | protein_coding | tolerated(0.13) | probably_damaging(0.943) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCL16 | SNV | Missense_Mutation | novel | c.340C>T | p.Pro114Ser | p.P114S | O15467 | protein_coding | tolerated_low_confidence(0.14) | benign(0.038) | TCGA-BG-A0VZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| CCL16 | SNV | Missense_Mutation | novel | c.338N>G | p.Gln113Arg | p.Q113R | O15467 | protein_coding | tolerated_low_confidence(0.35) | benign(0.284) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |